Literature DB >> 22180684

Medical reversal: why we must raise the bar before adopting new technologies.

Vinay Prasad1, Adam Cifu.   

Abstract

Medical reversal occurs when a new clinical trial - superior to predecessors by virtue of better controls, design, size, or endpoints - contradicts current clinical practice. In recent years, we have witnessed several instances of medical reversal. Famous examples include the class 1C anti-arrhythmics post-myocardial infarction (contradicted by the CAST trial) or routine stenting for stable coronary disease (contradicted by the COURAGE trial). In this paper, we explore the phenomenon of medical reversal. The causes and consequences are discussed. Conflicts of interest among researchers and an unyielding faith in basic science are explored as root causes of reversal. Reversal harms patients who undergo the contradicted therapy during the years it was in favor and those patients who undergo the therapy in the lag time before a change in medical practice. Most importantly, it creates a loss of faith in the medical system by physicians and patients. The solution to reversal is upfront, randomized clinical trials for new clinical practices and a systematic method to evaluate practices already in existence.

Entities:  

Keywords:  basic science; contradicted findings; evidence-based medicine; medical reversal; observational studies; randomized controlled trials

Mesh:

Year:  2011        PMID: 22180684      PMCID: PMC3238324     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  59 in total

1.  Evaluation of conflict of interest in economic analyses of new drugs used in oncology.

Authors:  M Friedberg; B Saffran; T J Stinson; W Nelson; C L Bennett
Journal:  JAMA       Date:  1999-10-20       Impact factor: 56.272

2.  Association between pharmaceutical involvement and outcomes in breast cancer clinical trials.

Authors:  Jeffrey Peppercorn; Emily Blood; Eric Winer; Ann Partridge
Journal:  Cancer       Date:  2007-04-01       Impact factor: 6.860

3.  Thoracic and lumbar vertebroplasties performed in US Medicare enrollees, 2001-2005.

Authors:  Darryl T Gray; William Hollingworth; Nneka Onwudiwe; Richard A Deyo; Jeffrey G Jarvik
Journal:  JAMA       Date:  2007-10-17       Impact factor: 56.272

4.  Percutaneous polymethylmethacrylate vertebroplasty in the treatment of osteoporotic vertebral body compression fractures: technical aspects.

Authors:  M E Jensen; A J Evans; J M Mathis; D F Kallmes; H J Cloft; J E Dion
Journal:  AJNR Am J Neuroradiol       Date:  1997 Nov-Dec       Impact factor: 3.825

5.  Optimal medical therapy with or without PCI for stable coronary disease.

Authors:  William E Boden; Robert A O'Rourke; Koon K Teo; Pamela M Hartigan; David J Maron; William J Kostuk; Merril Knudtson; Marcin Dada; Paul Casperson; Crystal L Harris; Bernard R Chaitman; Leslee Shaw; Gilbert Gosselin; Shah Nawaz; Lawrence M Title; Gerald Gau; Alvin S Blaustein; David C Booth; Eric R Bates; John A Spertus; Daniel S Berman; G B John Mancini; William S Weintraub
Journal:  N Engl J Med       Date:  2007-03-26       Impact factor: 91.245

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.

Authors: 
Journal:  N Engl J Med       Date:  1994-04-14       Impact factor: 91.245

8.  Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial.

Authors:  D S Echt; P R Liebson; L B Mitchell; R W Peters; D Obias-Manno; A H Barker; D Arensberg; A Baker; L Friedman; H L Greene
Journal:  N Engl J Med       Date:  1991-03-21       Impact factor: 91.245

9.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

Authors:  Steven E Nissen; Kathy Wolski
Journal:  N Engl J Med       Date:  2007-05-21       Impact factor: 91.245

10.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease.

Authors:  G S Omenn; G E Goodman; M D Thornquist; J Balmes; M R Cullen; A Glass; J P Keogh; F L Meyskens; B Valanis; J H Williams; S Barnhart; S Hammar
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245

View more
  20 in total

1.  Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Staphylococcus aureus Infection?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2020-06-01

2.  Failing to improve overall survival because post-protocol survival is long: fact, myth, excuse or improper study design?

Authors:  Vinay Prasad; Andrae Vandross
Journal:  J Cancer Res Clin Oncol       Date:  2014-01-29       Impact factor: 4.553

Review 3.  The reversal of cardiology practices: interventions that were tried in vain.

Authors:  Vinay Prasad; Adam Cifu
Journal:  Cardiovasc Diagn Ther       Date:  2013-12

Review 4.  Defining and Measuring the Affordability of New Medicines: A Systematic Review.

Authors:  Fernando Antoñanzas; Robert Terkola; Paul M Overton; Natalie Shalet; Maarten Postma
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

5.  Exploring Novel Computable Knowledge in Structured Drug Product Labels.

Authors:  Scott A Malec; Richard D Boyce
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2020-05-30

6.  The evidence base for US joint commission hospital accreditation standards: cross sectional study.

Authors:  Sarah A Ibrahim; Kelly A Reynolds; Emily Poon; Murad Alam
Journal:  BMJ       Date:  2022-06-23

7.  The case for intervention bias in the practice of medicine.

Authors:  Andrew J Foy; Edward J Filippone
Journal:  Yale J Biol Med       Date:  2013-06-13

Review 8.  Identifying low-value clinical practices in critical care medicine: protocol for a scoping review.

Authors:  Daniel J Niven; T Jared McCormick; Sharon E Straus; Brenda R Hemmelgarn; Lianne P Jeffs; Henry T Stelfox
Journal:  BMJ Open       Date:  2015-10-28       Impact factor: 2.692

Review 9.  Towards understanding the de-adoption of low-value clinical practices: a scoping review.

Authors:  Daniel J Niven; Kelly J Mrklas; Jessalyn K Holodinsky; Sharon E Straus; Brenda R Hemmelgarn; Lianne P Jeffs; Henry Thomas Stelfox
Journal:  BMC Med       Date:  2015-10-06       Impact factor: 8.775

10.  Sustainability in Health care by Allocating Resources Effectively (SHARE) 9: conceptualising disinvestment in the local healthcare setting.

Authors:  Claire Harris; Sally Green; Wayne Ramsey; Kelly Allen; Richard King
Journal:  BMC Health Serv Res       Date:  2017-09-08       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.